[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641513":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":17,"collaborators":7,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":26,"acronym":27,"eligibilityCriteria":28,"healthyVolunteers":23,"sex":29,"minAge":30,"maxAge":7,"enrollmentInfo":31,"targetDuration":7,"studyType":34,"phases":7,"briefSummary":35,"conditions":36,"keywords":39,"overallStatus":42,"whyStopped":7,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":7},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Weili Zhao","CONTACT","086-022-64370045","zwl_trial@163.com",{"name":15,"role":11,"phone":7,"phoneExt":7,"email":16},"Pengpeng Xu","pengpeng_xu@126.com",{"type":18,"investigatorFullName":19,"investigatorTitle":20,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Zhao Weili","Vice president of Ruijin Hospital","100641513","a-multi-center-prospective-registry-study-to-analyze-the-clinical-characteristics-and-prognosis-of-different-molecular-subtypes-of-peripheral-t-cell-lymphoma-100641513",false,"NCT07657572","A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.","Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (EXCELLENT Study)","EXCELLENT","Inclusion Criteria:\n\n* Patients diagnosed with peripheral T-cell lymphoma (PTCL) by histopathology from June 2026 to December 2029 and detected by gene sequencing (NGS) with different molecular subtypes.\n* Patients diagnosed with PTCL by histopathology from January 2026 to June 2026 and NGS detection can be performed if there is tumor tissue.\n* Fully understand the study, voluntarily sign the written informed consent form (ICF), and agree to cooperate with genetic testing, treatment, efficacy assessment and long-term follow-up.\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Female patients who are pregnant, breastfeeding, or of childbearing potential without effective contraception;\n* Subjects with poorly controlled neurological, psychiatric, mental or cognitive disorders that may impair their understanding and signing of the informed consent form as well as adherence to the study procedures;\n* Any other conditions deemed inappropriate for enrollment by the investigator.","ALL","18 Years",{"count":32,"type":33},1000,"ESTIMATED","OBSERVATIONAL","A multi-center, prospective, registry study to analyze the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma.",[37,38],"PTCL","T Cell Lymphoma",[40,41],"Peripheral T Cell Lymphoma","molecular subtypes","NOT_YET_RECRUITING","2026-06-14",{"date":45,"type":46},"2026-06-18","ACTUAL",{"date":48,"type":33},"2026-06",{"date":50,"type":33},"2030-12",{"name":5,"class":6}]